Effectiveness and cost-effectiveness of imatinib for first-line treatment of chronic myeloid leukaemia in chronic phase: a systematic review and economic analysis.
about
Case study of the comparison of data from conference abstracts and full-text articles in health technology assessment of rapidly evolving technologies: does it make a difference?Benefits of global partnerships to facilitate access to medicines in developing countries: a multi-country analysis of patients and patient outcomes in GIPAPGovernment use licenses in Thailand: an assessment of the health and economic impacts3,4-Dihydroxy-benzohydroxamic acid (Didox) suppresses pro-inflammatory profiles and oxidative stress in TLR4-activated RAW264.7 murine macrophages.Dasatinib: the emerging evidence of its potential in the treatment of chronic myeloid leukemia.The relative efficacy of imatinib, dasatinib and nilotinib for newly diagnosed chronic myeloid leukemia: a systematic review and network meta-analysis.Surface Defection Reduces Cytotoxicity of Zn(2-methylimidazole)2 (ZIF-8) without Compromising its Drug Delivery Capacity.Chronic myeloid leukemia (CML): association of treatment satisfaction, negative medication experience and treatment restrictions with health outcomes, from the patient's perspective.Advances in cancer therapeutics and patient access to new drugs.Systematic assessment of decision-analytic models for chronic myeloid leukemia.Raman spectroscopy using plasmonic and carbon-based nanoparticles for cancer detection, diagnosis, and treatment guidance. Part 2: Treatment.The in vivo toxicity of hydroxyurea depends on its direct target catalase.Cost-effectiveness of dasatinib versus high-dose imatinib in patients with Chronic Myeloid Leukemia (CML), resistant to standard dose imatinib--a Swedish model application.Economic evaluation of posaconazole vs. standard azole prophylaxis in high risk neutropenic patients in the Netherlands.Utility values for specific chronic myeloid leukemia chronic phase health states from the general public in the United Kingdom.Economic evaluation of posaconazole versus fluconazole or itraconazole in the prevention of invasive fungal infection in high-risk neutropenic patients in Sweden.Utility values for chronic myelogenous leukemia chronic phase health states from the general public in the United Kingdom.[Innovations with system disrupting potential? New drugs of high value].Clinical characteristics and therapeutic outcomes of elderly patients with chronic myeloid leukemia: A retrospective multicenter study.
P2860
Q31061524-7537C892-DA50-4723-BD1C-5DA6E7393090Q33589693-DE7B7431-A10C-4338-855B-CC01006EE2ECQ35222575-41BAF90F-622E-4CD8-AD88-C93CF5463386Q35533521-19E24997-0D5D-4CB6-9A9A-3E296F649275Q35876347-B25A8FB4-3608-4989-AE7A-B88B9524E982Q36649196-5450CB75-0B54-4680-BDA3-F7890BC4DD83Q36688333-F6FE321E-43A6-4880-89E1-E523A9141AACQ37365606-94FBF0A4-9629-4FBF-A776-148013E6D0D4Q37823895-0AB43325-863E-4B6D-803E-249568C7EF99Q38175353-23DA012C-881A-4463-9DC6-E01960052299Q39180555-770C6884-CB10-45CB-8317-A9884AAFB4CBQ42737452-5451DD36-0ED7-4273-A557-2B27FCE44E6DQ42976135-100DC3B6-C2CF-402A-9337-BE0D9598D922Q43470906-36328800-46DC-48F4-9648-9CA85A611C7EQ43519867-B784E2C4-7AE8-47DD-9827-74329BA07F6BQ44482692-35122204-B048-41F6-92B0-C05BA8D0E38FQ48572294-147F532C-105E-4B96-A280-1F8BDFCAB2AFQ52588893-7448AD5B-E0CC-4C17-8134-532927650065Q55070999-D85E6879-759C-4E97-A0B6-69C424A95E32
P2860
Effectiveness and cost-effectiveness of imatinib for first-line treatment of chronic myeloid leukaemia in chronic phase: a systematic review and economic analysis.
description
2004 nî lūn-bûn
@nan
2004 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Effectiveness and cost-effecti ...... review and economic analysis.
@ast
Effectiveness and cost-effecti ...... review and economic analysis.
@en
type
label
Effectiveness and cost-effecti ...... review and economic analysis.
@ast
Effectiveness and cost-effecti ...... review and economic analysis.
@en
prefLabel
Effectiveness and cost-effecti ...... review and economic analysis.
@ast
Effectiveness and cost-effecti ...... review and economic analysis.
@en
P2093
P356
P1476
Effectiveness and cost-effecti ...... review and economic analysis.
@en
P2093
P304
iii, 1-120
P356
10.3310/HTA8280
P577
2004-07-01T00:00:00Z